MCL1 and neuroblastoma: Additionally, genes associated with activation of RAS-MAPK signaling are mutated in 65% of relapsed tumors [12], and overexpression of the anti-apoptotic proteins Bcl-2 and Mcl-1 is implicated in the poor response of NB to therapy [13,14].